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OBJECTIVES This study aimed to characterize the clinical profile of familial dilated cardiomyopathy (FDC)
in the families of four index patients initially diagnosed with idiopathic dilated cardiomyop-
athy (IDC) and to provide clinical practice recommendations for physicians dealing with
these diseases.
BACKGROUND Recent evidence indicates that approximately one-half of patients diagnosed with IDC will
have FDC, a genetically transmissible disease, but the clinical profile of families screened for
FDC in the U.S. has not been well documented. Additionally, recent ethical guidelines
suggest increased responsibilities in caring for patients with newly found genetic cardiovas-
cular disease.
METHODS After identification of four families with FDC, we undertook clinical screening including
medical history, physical examination, electocardiogram and echocardiogram. Diagnostic
criteria for FDC-affected status of asymptomatic family members was based on left
ventricular enlargement (LVE). Subjects with confounding cardiovascular diagnoses or body
mass indices .35 were excluded.
RESULTS We identified 798 living members from the four FDC pedigrees, and screened 216 adults and
129 children (age ,16 years). Twenty percent of family members were found to be affected
with FDC; 82.8% of those affected were asymptomatic. All four pedigrees demonstrated
autosomal dominant patterns of inheritance. The average left ventricular end-diastolic
dimension was 61.4 mm for affected and 48.4 mm for unaffected subjects, with an average age
of 38.3 years (614.6 years) for affected and 32.1 years for unaffected subjects. The age of onset
for FDC varied considerably between and within families. Presenting symptoms when
present were decompensated heart failure or sudden death.
CONCLUSIONS We propose that with a new diagnosis of IDC, a thorough family history for FDC should be
obtained, followed by echocardiographic-based screening of first-degree relatives for LVE,
assuming their voluntary participation. If a diagnosis of FDC is established, we suggest
further screening of first-degree relatives, and all subjects with FDC undergo medical
treatment following established guidelines. Counseling of family members should emphasize
the heritable nature of the disease, the age-dependent penetrance and the unpredictable
clinical course. (J Am Coll Cardiol 1999;34:837–47) © 1999 by the American College of
Cardiology
Heart failure is a major cause of death and disability in
several million U.S. citizens resulting principally from isch-
emic and idiopathic dilated (IDC) cardiomyopathies. Isch-
emic cardiomyopathy results from loss of myocardium from
one or more myocardial infarctions. In contrast, the causes
of IDC have been postulated to result from a variety of viral,
toxic or environmental injuries (1) and, more recently,
familial transmission. Early in this decade, it was suggested
that up to 20% of patients initially diagnosed with IDC would
have familial disease (2,3). More recent results (4,5) suggest
that from 35% to 48% of patients with IDC may have familial
disease. This familial disease most commonly follows a Men-
delian dominant inheritance pattern (4–6), and thus has been
postulated to represent genetic disease. In support of this
genetic hypothesis are reports of six pedigrees with autosomal
dominant transmission and positive linkage to five chromo-
somes (6–11) or to actin in two very small pedigrees (12).
These data suggest that familial dilated cardiomyopathy
(FDC) involves several different genes or gene families.
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Thus, we now understand that a patient newly diagnosed
with IDC has a one in three or greater chance of having a
serious, potentially life-threatening heritable myocardial
disease. This new insight of genetic cardiomyopathy neces-
sitates scrutiny of our current practice patterns. Are our
current diagnostic and therapeutic approaches adequate for
patients newly diagnosed with IDC? If IDC represents a
heritable disease, what obligations do we have to the
potentially affected family members? In 1993, we estab-
lished a research program to identify and characterize
families with FDC and to determine the molecular basis of
FDC. We have screened numerous patients who by family
history may have FDC, and have undertaken clinical screen-
ing of four large families. In this paper, we present the
clinical characteristics of these families, and we base our
clinical practice recommendations on these observations.
METHODS
Oregon Health Sciences University (OHSU) program
description and FDC screening questionnaire. An FDC
research program was established at the OHSU in 1993 to
determine the molecular basis of FDC. All new patients
who were referred to the clinic of the Oregon Heart Failure
Treatment Program at OHSU after informed consent were
asked to complete an FDC screening questionnaire contain-
ing questions regarding their diagnosis, duration, symptoms
and etiology of heart failure, including detailed information
on family history. A patient was diagnosed as having FDC
if IDC was present in one first-degree relative or two
second-degree relatives. We selected four index patients
with large families consisting of three or more living
generations for prospective and comprehensive clinical
screening for FDC.
Clinical screening of families. Informed consent was ob-
tained from all subjects. Adult relatives of each index patient
were contacted either by phone or by mail to obtain personal
medical histories and demographic information. Pedigree
construction for each family was undertaken. Medical
records and/or death certificates were retrieved. Each family
member was offered clinical screening consisting of a med-
ical history, a physical examination, a 12-lead electrocardio-
gram (ECG) and a two-dimensional and M-mode ECG.
diogram. Local and distant clinical screenings were con-
ducted between 1993 and 1998 for OHSU FDC-1, 2, 3 and
4. Initial clinical screening has been completed for FDC-1;
clinical screening for FDC-2, 3 and 4 is still in progress.
History and physical examination. The medical history
documented cardiovascular disease including hypertension,
heart disease, arrhythmia, stroke or transient ischemic
attacks, diabetes mellitus, lung and thyroid disease. Review
of systems included questions about dyspnea on exertion,
orthopnea, paroxysmal nocturnal dyspnea, energy level,
appetite, weight change, edema, activity level, chest pain,
palpitations and syncope or presyncopal symptoms. Addi-
tionally, we obtained a pregnancy history and a history for
alcohol, tobacco, medication and illicit drug use from each
family member. The physical examination included vital
signs, weight and height measurements, as well as assess-
ment for elevated jugular venous pressure, carotid artery
quality, bruits, lifts, heaves, quality and location of the point
of maximal impulse, presence of a third or fourth heart
sound, murmurs, quality of breath sounds, hepatic size and
presence of peripheral edema.
Echocardiographic methods. Echocardiograms were per-
formed by experienced operators without knowledge of the
family member’s clinical data, using high-quality echocar-
diographic equipment. Two-dimensional and M-mode
parasternal long- and short-axis views were obtained in
addition to apical four- and two-chamber views. Examina-
tions were recorded on VHS videocassette tapes and strip
charts when possible, using 2.5- and 3.5-MHz transducers.
The echocardiograms were independently reviewed by two
experienced physicians to verify the accuracy of measure-
ments and to interpret the studies. Measurements were
taken from the parasternal long- or short-axis M-mode or
two-dimensional views. Left ventricular dimensions were
measured according to the American Society of Echocardi-
ography.
We defined left ventricular enlargement (LVE) in sub-
jects 16 years of age or older as a left ventricular end-
diastolic dimension (LVEDD) . Framingham 97.5 per-
centile standard (13). This method is gender and height
specific, and its use is based on the recommendation by
Vasan et al., who analyzed echocardiographic data from the
Framingham Heart Disease Study (14). The 97.5 percentile
values of LVEDD are calculated as:
Males: LVEDD97.5 5 exp ~3.5990 1 0.5721 3 lnHeight
1 1.96 3 0.0835!
Females: LVEDD97.5 5 exp ~3.5856 1 0.4963 3 lnHeight
1 1.96 3 0.0635!
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
BMI 5 body mass index
ECG 5 electrocardiogram
FDC 5 familial dilated cardiomyopathy
HCM 5 hypertrophic cardiomyopathy
ICD 5 internal cardiac defibrillator
IDC 5 idiopathic dilated cardiomyopathy
LVE 5 left ventricular enlargement
LVEDD 5 left ventricular end-diastolic dimension
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
OHSU 5 Oregon Health Sciences University
SOLVD 5 Studies of Left Ventricular Dysfunction
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Assignment of affected, nonaffected and indeterminate
status. All assignments were based on the phenotype ob-
served at screening, or on medical records to establish the
diagnosis of IDC. Subjects of all ages were classified as
affected if they had an established diagnosis of IDC, or they
were 16 years of age or older with LVE (13) and no other
confounding issues. Patients of all ages with normal LV size
were classified as nonaffected regardless of other confound-
ing issues. Indeterminate status was assigned to two cate-
gories of subjects: 1) those without echo data (nonevaluable,
usually from no echo window), and 2) those with LVE, but
also with some other confounding cardiovascular diagnosis
or other cardiovascular abnormality detected in the screen-
ing protocol or age ,16 years of age. Cardiovascular
diagnoses included a history of severe and/or uncontrolled
hypertension (defined as repeated systolic blood pressures .
160 mm Hg and/or diastolic blood pressures . 100 mm Hg),
a history of hypertension that was treated with medications,
any history of ischemic heart disease, congenital heart
disease, intrinsic valvular disease, history of cardiotoxic
chemotherapy or radiation therapy involving the chest, or
with moderately severe obesity defined as a body mass index
(BMI) greater than 35 kg/m2. These criteria for the assign-
ment of affected, nonaffected and indeterminate status are
referred to as the OHSU FDC diagnostic criteria (13).
Statistical analysis. When comparing the characteristics of
family members with and without the FDC phenotype, we
subsequently excluded the family members who had a
history of hypertension or coronary artery disease, an inad-
equate echocardiogram or BMI .35 kg/m2. The Student t
test and chi-square test or Fisher exact test were used for the
comparison. Statistical significance indicates p , 0.05
unless otherwise noted. The statistical analysis was per-
formed using statistical software SPSS-PC (SPSS Inc.,
Chicago, Illinois).
RESULTS
Pedigree descriptions and clinical profiles. We identified
a total of 798 living members from the four FDC pedigrees.
Clinical screening has been completed in 345 family mem-
bers, and their clinical characteristics are given (Table 1).
Approximately 40% of family members from each pedigree
were children (age ,16-years-old). The median age of
screened family members was 21.4 years (range 8 months to
75 years). The age distribution was similar in the four
pedigrees. Approximately 1 out of 10 relatives had a history
of hypertension. The average body surface area and BMI are
comparable across the four pedigrees.
OHSU FDC-1. The index patient of OHSU FDC-1 (Fig.
1) was 63 years old at the time of identification. She was a
New York Heart Association (NYHA) functional class 2
when diagnosed with IDC at 49 years of age. Her symptoms
have progressed and she is currently a NYHA functional
class 3. Her LVEDD is 70 mm with a fractional shortening
of 14%; her left ventricular ejection fraction (LVEF) is
0.35. Her ECG shows a left bundle branch block. She
has been treated with conventional medications including
angiotensin-converting enzyme (ACE) inhibitors, digoxin,
diuretics and beta blockers. Her oldest daughter (V-A) and
Table 1. Characteristics of Four Large OHSU FDC Pedigrees
FDC-1 FDC-2 FDC-3 FDC-4 Total
Total living 158 104 481 55 798
Total screened 107 59 152 27 345
Children (,16 yrs) (%) 46 (43.0) 17 (28.8) 56 (36.8) 10 (37.0) 129 (37.4)
Adults (%) 61 (57.0) 42 (71.2) 96 (63.2) 17 (63.0) 216 (62.6)
Age at screening (yrs) 23 20 24 18.8 21.4
Median (range) (1–65) (5–75) (0.67–75) (1.8–47.0) (0.7–75.0)
Gender
Male (%) 50 (46.7) 32 (54.2) 72 (47.4) 15 (55.6) 169 (49.0)
Female (%) 57 (53.2) 27 (45.8) 80 (52.6) 12 (44.4) 176 (51.0)
Smoker 35 (32.7) 10 (16.9) 44 (28.9) 9 (33.3) 98 (28.4)
Former (%) 8 (7.5) 3 (5.1) 13 (8.5) 6 (22.2) 30 (8.7)
Current (%) 27 (25.2) 7 (11.9) 31 (20.4) 3 (11.1) 68 (19.7)
Medical history
Hypertension 3 (2.8) 6 (10.2) 21 (13.8) 1 (3.7) 31 (9.0)
Diabetes 3 (2.8) 2 (3.4) 5 (3.3) 0 10 (2.9)
Arrhythmias 4 (3.7) 7 (11.9) 6 (3.9) 1 (3.7) 18 (5.2)
Coronary artery disease 1 (0.9) 1 (1.7) 1 (0.7) 0 3 (0.9)
BSA (m2) 1.75 1.85 1.80 1.87 1.84
Median (range) (0.47–2.54) (0.83–2.61) (0.24–2.92) (0.54–2.41) (0.25–2.9)
BMI (kg/m2) 25.1 24.9 26.0 24.5 25.6
Median (range) (12.6–52.9) (14.5–47.4) (13.8–110.9) (15.5–34.5) (12.6–110.9)
BMI 5 body mass index; BSA 5 body surface area; FDC 5 familial dilated cardiomyopathy; OHSU 5 Oregon Health Sciences University.
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a distant cousin (IV-G) had symptomatic IDC confirmed
by medical records and formed the basis for diagnosis of
FDC; both were treated with ACE inhibitors, and left
ventricular size and function have improved.
OHSU FDC-1 had a low prevalence of hypertension,
diabetes and coronary artery disease (Table 1). All members
of the first three generations were deceased; medical histo-
ries suggest that four of the seven members of generation III
may have had heart failure (III-A, III-B, III-C, III-D), and
these subjects died in their fifth and sixth decades of life.
One hundred seven of 158 living family members ranging
from 1 to 65 years of age were screened (Table 1). Six family
members (IV-E, IV-F, V-B, V-C, V-D, VI-A) were
identified by prospective screening as affected. All were
asymptomatic with normal cardiovascular physical examina-
tions. Subjects IV-B and IV-C were classified as indeter-
minate because of poor-quality echocardiograms. Subjects
IV-D and V-E were classified as indeterminate because of
BMI .35 kg/m2 and exposure to cardiotoxic chemother-
apy, respectively.
Pedigree analysis suggests an autosomal dominant pattern
of inheritance (Fig. 1). This family expresses a mild form of
FDC with the onset of symptoms occurring in mid to later
in life. The index patient and symptomatic family members
have responded favorably to medical therapy.
OHSU FDC-2. One of the unique aspects of the OHSU
FDC-2 pedigree is that the index patient has both a
maternal and paternal family history of dilated cardiomy-
opathy (Fig. 2). The index patient for OHSU FDC-2 was
14 years old when he was identified. He was asymptomatic
until May 1993, when he became acutely short of breath and
was hospitalized with a diagnosis of heart failure; his
LVEDD was 71 mm with a fractional shortening of 11%;
his LVEF was 0.15. His ECG showed a Q-wave pattern in
V1-V4. He was diagnosed with IDC and underwent emer-
gent heart transplantation in June 1993. Routine his-
topathologic examination was unrevealing and consistent
with IDC. This family came to our attention when a
previously healthy 17-year-old maternal cousin (V-C) was
resuscitated from ventricular fibrillation in November 1994.
He was found to have an LVEDD of 52 mm and severely
reduced left ventricular systolic function. Coronary angiog-
raphy revealed normal coronary arteries. Conventional med-
ical therapy with ACE inhibitors was initiated. He later had
an internal cardiac defibrillator (ICD) placed. His ventric-
ular function has improved. This event prompted careful
medical and family histories for both parents of the index
patient. Remarkably, at prospective screening, both parents
were found to have IDC, and on that basis a diagnosis of
Figure 1. Pedigree of OSHU FDC-1. OHSU FDC-1 is a white family comprised of 165 relatives. It has seven generations (circa 1850
to 1995). The family has a wide geographic distribution ranging from Alaska and the western U.S. to the Midwest and southern U.S.
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FDC was assigned. Complete family screening of both
maternal and paternal pedigrees was then undertaken.
A total of 59 relatives from 5 to 75 years of age have been
screened (Table 1). Five additional family members (IV-B,
IV-C, IV-D, V-A, V-D) were identified by prospective
screening as affected, and all were asymptomatic except
IV-B (the index patient’s father), who was found to be in
previously undetected decompensated heart failure. Coro-
nary angiography revealed normal coronary arteries, and he
was started on digitalis, diuretics and ACE inhibitors.
Three months after subject IV-D was identified as being
affected by prospective screening, he experienced sudden
cardiac death, was successfully resuscitated and received an
ICD. Three subjects were classified as indeterminate: sub-
ject IV-A had a BMI . 35 kg/m2, subject IV-E was an elite
athlete and subject IV-F had a poor-quality echocardiogram.
Pedigree analysis of FDC-2 suggests an autosomal dom-
inant pattern of inheritance (Fig. 2). The clinical profile of
this two-family pedigree is complex. Onset of disease in the
FDC-2B (maternal pedigree) ranges from the second to
fourth decade of life. Initial symptoms of disease in
FDC-2B are lethal arrhythmias. Affected subjects in
FDC-2A present with symptoms of decompensated heart
failure and congestion. Notably, the index patient and his
two siblings may carry either the maternal or the paternal
FDC gene, or both, even though only one sibling had LVE
at the time of screening.
OHSU FDC-3. The OHSU FDC-3 index patient (Fig. 3)
was a 43-year-old woman who was referred to our clinic for
consideration of cardiac transplantation in September 1995.
She had been diagnosed with IDC after 7 months of
increasing dyspnea on exertion and fatigue. Her LVEDD
was 71 mm with a fractional shortening of 14%; her LVEF
was 0.21 and her ECG showed ventricular bigeminy.
Despite full medical therapy and stable NYHA class III
symptoms, she died of sudden cardiac death in October
1996. The FDC diagnosis was established as family history
revealed that her mother (III-B) and her maternal grandfa-
ther (II-A) died of heart failure at 59 and 52 years of age,
respectively, and that three deceased siblings (IV-E, IV-F,
IV-H) had IDC confirmed by medical records and/or death
certificates (Fig. 3).
A total of 152 relatives ranging from eight months to 75
years of age have been screened (Table 1). Of five adult
family members identified by prospective screening as af-
fected, four were asymptomatic (III-E, IV-M, V-C, V-E);
subject IV-G was symptomatic at the time of screening with
Figure 2. Pedigree of OHSU FDC-2. OHSU FDC-2 is comprised of two Caucasian families spanning five generations that includes 20
paternal (A) and 84 maternal (B) relatives. The index patient’s paternal grandmother (III-A) died from dilated cardiomyopathy at the age
of 51 years. The geographic distribution of these families range from the Pacific Northwest to the Midwest and southern U.S. The number
19 below the subject symbol and the number in parentheses (#4) denote the number of known descendants and the number of screened
subjects, respectively, not shown due to space limitations.
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an LVEDD of 70 mm. Despite being treated with ACE
inhibitors and other conventional medications, he died
suddenly. At the time of screening, subject IV-K was found
to have LVE, moderately reduced left ventricular function
and mild symptoms of heart failure, but she was classified as
indeterminate because of uncontrolled hypertension. IV-D
was indeterminate because of poor-quality echo data. Eight
other subjects were classified as indeterminate because of
hypertension and/or obesity. FDC-3 has the highest prev-
alence of hypertension and obesity among the four pedigrees
(Table 1). Pedigree analysis suggests an autosomal domi-
nant pattern (Figure 3).
This African-American family is the first reported with
FDC. The onset of symptoms occurs in the fifth and sixth
decades of life and is expressed as congestive heart failure
and/or sudden cardiac death. The disease progresses despite
conventional medical therapy.
OHSU FDC-4. The OHSU FDC-4 index patient was 23
years old when diagnosed with IDC and progressive heart
failure (Fig. 4). He was referred to us for consideration of
cardiac transplantation in March 1997. His LVEDD was
75 mm; his LVEF was 0.19. His ECG showed a left bundle
branch block with Q-waves in V1-V3. Despite intensive
medical treatment, he experienced rapid progression of
heart failure and underwent cardiac transplantation in Au-
gust 1997. Familial dilated cardiomyopathy was diagnosed
by family history, which revealed that his paternal grandfa-
ther (II-A) died from heart failure in his 40s, and just before
his transplant, a 35-year-old paternal aunt (III-K) was
confirmed to have IDC and was also listed for heart
transplant at another medical center. More recently, a
44-year-old paternal uncle (III-C) died from newly diag-
nosed IDC. Medical records have confirmed IDC and the
absence of coronary artery disease in the deceased subjects
II-A and II-B.
Characteristics of this family are presented (Table 1).
This family has a low incidence of hypertension and no one
was identified with diabetes or coronary artery disease. To
date, 27 family members have been screened. An additional
eight asymptomatic family members (III-B, III-D, III-F,
Figure 3. Pedigree of OHSU FDC-3. FDC-3 is a very large African-American family spanning eight generations with 481 living relatives
who are related to the index patient by her maternal grandfather. All members of generations I and II are deceased and only four members
of generation III are living. FDC-3 has a broad geographic distribution with most of the family residing in the midwestern and southern
U.S., and a small portion reside in the Pacific Northwest. Numbers below the subject symbols and numbers in parentheses, i.e. (#10),
denote the number of known descendants and the number of screened subjects, respectively, not shown due to space limitations.
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III-H, IV-A, IV-B, IV-C, IV-D) were identified by pro-
spective screening as affected with FDC. Subjects III-A and
III-E were classified as indeterminate because of a poor-
quality echo and hypertension, respectively. One striking
feature of this pedigree is the high level of penetrance (9 of
14 evaluable subjects, 64.3%). Pedigree analysis reveals an
autosomal dominant pattern of inheritance. Subject III-G is
an obligate carrier based on the pedigree, but has not
manifested LVE at this time. Clinical screening continues
for this family.
Data summary from all pedigrees. Of the 29 family mem-
bers identified as affected with FDC, 24 were asymptomatic
(82.8%), and are compared with nonaffected subjects from the
four pedigrees (Table 2). A significant difference was observed
in fractional shortening and the percentage of ECG abnor-
malities between affected and nonaffected subjects. The ECG
abnormalities were nonspecific between pedigrees and con-
sisted primarily of bundle branch block.
The disease phenotype, LVE, occurred as early as the
second decade (Fig. 5). Although LVE increased in all four
families after 35 years of age, the frequency of LVE differed
considerably from family to family (Fig. 5). The variable and
age-dependent penetrance of FDC has been previously
noted with greater than 80% penetrance by 50 years of age
(15). Thus, the data demonstrate a variation in the onset
and frequency of LVE among families with FDC, and the
descriptive data reflect wide variability in the onset of
symptomatic heart failure or sudden cardiac death.
DISCUSSION
We have presented the clinical profiles and characteristics of
four large pedigrees with FDC identified in our program
from index patients initially diagnosed with IDC. These
pedigrees demonstrate autosomal dominant patterns of
inheritance, the most common transmission of FDC (4–6).
We also noted that most of the family members who
underwent prospective clinical screening and were classified
as affected by echocardiographically determined LVE were
free of any signs or symptoms of cardiovascular disease.
Consistent with previous studies (15), the age of onset of
symptomatic clinical disease varied considerably between
families and between individuals within the same family,
and presenting symptoms were usually decompensated heart
failure or sudden death. We suggest that these observations
lay the foundation to change the clinical practice of physi-
cians who care for patients diagnosed with IDC and FDC.
The conventional diagnosis of IDC rests upon cardiac
enlargement associated with decreased systolic function
(i.e., an ejection fraction less than 0.50) after other causes of
cardiomyopathy have been excluded, including most com-
monly ischemic, valvular, inflammatory or infiltrative car-
diomyopathies. If a diagnosis of clinical heart failure is
appropriate, conventional medical therapy based upon ACE
inhibitors, beta blockers and diuretics is indicated, as is
education addressing diet, activity, medication usage and
prognosis (16).
Because recent work has suggested that familial disease
may account for at least 35% to 48% (4,5) of patients
diagnosed with IDC, we propose that for patients with
newly diagnosed IDC, additional consideration should be
given to the elucidation of familial disease. Other genetically
based and transmissible cardiovascular diseases have been
described such as hypertrophic cardiomyopathy (HCM),
which has an estimated incidence of 2.5/100,000 person-
years and a prevalence of 19.7/100,000 (17). As recently
Figure 4. Pedigree of OHSU FDC-4. OHSU FDC-4 is a white pedigree that is comprised of 55 relatives from four living generations.
Family members are located in the Pacific Northwest, the Southwest and the East Coast.
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comprehensively reviewed (18), HCM has received exten-
sive clinical and genetic investigation with medical, surgical
and antiarrhythmic strategies for the treatment of affected
individuals. Screening by history, exam and echocardiogra-
phy of first-degree relatives of patients with HCM has been
advocated for several years (19–21), with recent updated
Figure 5. Cumulative rate of FDC by age group.
Table 2. Clinical Characteristics of Adult Family Members (.16 Years) With and Without
Phenotype of Familial Dilated Cardiomyopathy
Characteristic
With Phenotype
(n 5 29)
Without Phenotype
(n 5 114*)
p
Value
FDC family
FDC-1 9 (31.0) 41 (36.0)
FDC-2 5 (17.2) 19 (16.7)
FDC-3 6 (20.7) 49 (43.0)
FDC-4 9 (31.0) 5 (4.4)
Gender 0.50
Male (%) 14 (48.3) 63 (55.3)
Female (%) 15 (51.7) 51 (44.7)
Age at screening (yrs) 38.3 6 14.6† 32.1 6 12.5 0.02
Physical exam
Height (cm) 171.6 6 9.3 172.3 6 9.8 0.73
Weight (kg) 89.2 6 22.7 84.2 6 25.0 0.24
Heart rate (beats/min) 74.0 6 17.1 72.0 6 10.8 0.43
Body surface area (kg/m2) 1.9 6 0.2 1.9 6 0.2 0.64
Body mass index (kg/m2) 27.2 6 3.8 26.1 6 4.3 0.20
Blood pressure (mm Hg)
Systolic 122.9 6 15.7 119.1 6 13.4 0.20
Diastolic 76.8 6 11.1 73.2 6 11.7 0.14
ECG (%) , 0.01
Abnormal 11 (39.3) 25 (21.9)
Borderline 1 (3.6) 0
Echocardiographic
LVEDD (mm) 61.4 6 6.3 48.4 6 5.0 , 0.01
Fractional shortening (%) 27.3 6 9.9 36.4 6 8.6 , 0.01
*Excludes members with hypertension (n 5 25), coronary artery disease (n 5 3), inadequate echocardiogram (n 5 15) and body
mass index $35 kg/m2 (n 5 26). †Values are means 6 SD.
ECG 5 electrocardiogram; FDC 5 familial dilated cardiomyopathy; LVEDD 5 left ventricular end-diastolic dimension.
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diagnostic criteria for adults in affected families (20). For
HCM, it is recommended that any intervention be individ-
ualized, as the heterogeneity of HCM disease presentation
and progression has limited the utility of generic treatment
recommendations, especially for asymptomatic or mildly
symptomatic patients (18–20). Screening for HCM and
other cardiovascular genetic syndromes has also received
additional attention in recent reviews outlining ethical
mandates in genetic disease, with the foundational princi-
ples that screening activities must be voluntary from those
potentially affected family members after full disclosure, and
screening results must be combined with expert counseling
for those found to be affected (21,22).
The situation with FDC is quite similar in some respects
to that of HCM and in other respects fundamentally
different. Similarities include the reality that affected family
members in FDC (this work and others) or HCM (18,20)
pedigrees are frequently asymptomatic. Also, both diseases
can be life threatening from arrhythmias or heart failure,
although the latter is more common with FDC. Differences
include a twice-greater incidence and prevalence of IDC
estimated at 6 per 100,000 person-years and 36.5 per
100,000, respectively (17). Perhaps the most fundamental
difference is that FDC, as a subset of IDC, already has
established clinical guidelines for the treatment of asymp-
tomatic and symptomatic LVE based on extensive clinical
investigation over the last 10 to 15 years (16), and these
guidelines provide a foundation for generic recommenda-
tions regarding FDC.
For LVE in otherwise asymptomatic individuals, the use
of ACE inhibitors demonstrated less progression to symp-
tomatic heart failure in the Studies of Left Ventricular
Dysfunction (SOLVD) prevention trial (23). For LVE in
symptomatic patients, ACE inhibitors improved survival
and quality of life (24–27). Even though the SOLVD and
other trials with ACE inhibitors (24–27) were performed in
patients with two fundamentally different etiologic causes of
heart failure (ischemic and idiopathic dilated cardiomyopa-
thies), the responses to therapy were similar with both
etiologies. Based on the likelihood that from one-third to
one-half of these patients assigned as IDC in these studies
had FDC, these studies support the use of conventional
medical treatment with ACE inhibitors for FDC to im-
prove survival and prevent progression of disease. For FDC,
this may be particularly relevant for screening of family
members with asymptomatic LVE (23). The use of beta
blockers in combination with ACE inhibitors may also be
appropriate in these settings (28–30).
Clinical recommendations. Thus, the rationale for the
clinical recommendations that follow are based on the
serious, life-threatening nature of an IDC or FDC diagno-
sis, the ability to detect LVE easily and noninvasively by
echocardiography with stringent, sensitive and reliable di-
agnostic echocardiographic criteria (13) and the knowledge
that generic medical intervention with established treatment
protocols has a reasonable chance to affect the natural
history of FDC. Based on these considerations, and assum-
ing the voluntary participation of family members after
comprehensive informed consent and the availability of
counseling for all subjects as needed, we propose the
following.
1. A search for an FDC diagnosis is appropriate when IDC
is diagnosed.
a. Family history. With a new diagnosis of IDC, a
thorough cardiovascular family history should be
obtained regarding first- and second-degree relatives
who have known heart disease, heart failure or sudden
death. If one first-degree or two second-degree rela-
tives have been diagnosed with IDC, a diagnosis of
FDC should be assigned.
b. Echocardiographic screening. We suggest that echocar-
diographic screening for LVE is appropriate in first-
degree relatives of patients diagnosed with IDC
regardless of the cardiovascular family history. If LVE
is discovered, a thorough medical evaluation should
be undertaken to exclude other cardiovascular disease,
and once excluded, a presumptive diagnosis of FDC
should be assigned. The utility of screening of chil-
dren (,16 years) is unclear due to the difficulty
assigning LVE in this group and the age-dependent
penetrance. If the family history and echo screening
are negative, we advocate no further screening activ-
ities to establish the FDC diagnosis.
2. If the diagnosis of FDC is established in a kindred, we
suggest that stepwise echo screening is indicated for
first-degree relatives of those individuals diagnosed with
FDC. We propose that first-degree relatives of those
individuals diagnosed with FDC undergo echocardio-
graphic screening for LVE. If additional affected subjects
are identified, we propose that all first-degree relatives of
those affected should undergo screening in a progressive
stepwise format. For example, in the OHSU FDC-4
pedigree, after the assignment of the FDC diagnosis in
the index patient (IV-8) based on IDC diagnoses in two
second-degree relatives, we screened the index patient’s
father (III-9) (step 1) and found him to be affected by
our diagnostic criteria, who in turn had eight siblings (his
first-degree relatives). They underwent stepwise screen-
ing (step 2), and as shown, several additional family
members were found to be affected (Fig. 4). By this
recommendation, the first-degree relatives of those af-
fected individuals from step 2 should likewise undergo
screening (step 3). Thus, it is possible that progressive
stepwise screening will identify affected individuals
throughout an extended family.
We suggest routine screening beyond first-degree
relatives for clinical purposes is probably not indicated
based on our present experience, although we note that
by strict application of this guideline, the three affected
children of subject III-14 in the FDC-4 pedigree would
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not have been identified as he did not have LVE at the
time of screening and thus was classified as unaffected.
We propose two caveats to this recommendation: for an
extended FDC family, we suggest that medical evalua-
tions of members with unexplained cardiovascular symp-
toms is always appropriate; and if requested or for
particularly aggressive disease, screening of second-
degree relatives for LVE in some pedigrees may also be
appropriate.
3. Treatment intervention. For all subjects diagnosed with
FDC, we propose generic treatment with ACE inhibi-
tors (and possibly beta blockers), as has been previously
recommended for patients with IDC and asymptomatic
LVE, or IDC and symptomatic heart failure (16).
4. FDC counseling. Family members diagnosed with FDC
should be counseled that FDC has an unpredictable
clinical course, which ranges from one that is relatively
benign with conventional treatment to one of progressive
heart failure, which may result in heart transplantation or
sudden cardiac death. Additionally, affected family
members should be informed that they have a heritable
disease with a genetically transmissible risk to their
offspring (50% probability with Mendelian dominant
inheritance). Finally, those who are genetically at risk but
have no evidence of LVE should be counseled about the
age-dependent penetrance, the possibility of future dis-
ease presentation, and the recommendation for future
surveillance screening, or screening at any time with
symptoms of cardiac dysfunction.
5. Surveillance screening. Although firm recommendations
are difficult, surveillance screening is probably indicated
on a three- to five-year basis for first-degree relatives
who at initial screening have been shown to be clinically
unaffected.
Limitations. We recognize several limitations to the
present work. First, although the clinical effectiveness of
screening first-degree relatives of those with IDC to estab-
lish the diagnosis of FDC is apparent and is congruent with
HCM recommendations, the cost effectiveness of FDC
screening has not yet been validated. We suggest, however,
that the potential benefit of early therapy for LV dysfunc-
tion to prevent symptomatic or progressive heart failure (23)
in the subset of individuals found to have LVE will likely
outweigh the costs of screening and drug treatment. The
evaluation of comprehensive costs associated with screening
of first-degree relatives will require a prospective design and
is being initiated in our FDC research program at this time.
Second, the lack of genotypic data for FDC limits predictive
and prognostic information. Based upon multiple loci from
the reports of FDC pedigrees from other groups (6–11) and
the exclusion of these loci in the OHSU pedigrees presented
here (Hershberger et al. (13), unpublished data), the mo-
lecular causes of FDC will be polygenic. Thus, it is possible
that certain FDC genotypes will respond more or less
favorably to these drug interventions. These shortcomings
may be more easily addressable for FDC as disease genes are
identified, and as multiplexing gene technology emerges
that will permit rapid and simultaneous screening of many
genotypes, which will allow the creation of large databases
to predict clinical outcomes based on genotypic data. Third,
the echocardiographic screening for children (defined by our
group as age ,16 years) is problematic because of the lack
of large, population-based standards for normal left ventri-
cle size in children. Linear growth may be the major
determinant of cardiac growth, and therefore of cardiac
dimensions in children (31,32), but a host of factors
influence normal childhood growth. A similar problem has
been noted for screening of HCM in children (20).
Summary. In summary, we have demonstrated autosomal
dominant patterns of inheritance in four large FDC pedi-
grees and that the age of onset of symptomatic clinical
disease varies considerably among individuals. We have also
demonstrated that family screening will reveal asymptom-
atic disease in first-degree relatives. This collective experi-
ence combined with extensive clinical research regarding the
treatment of symptomatic and asymptomatic LVE and left
ventricular dysfunction have led to preliminary recommen-
dations for clinical practice relevant to FDC.
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